FDG PET and FES PET Predict PFS on Endocrine Therapy—Letter

Lemonitsa H. Mammatas,Erik J. van Helden,Henk M.W. Verheul,Catharina W. Menke-van der Houven van Oordt

CLINICAL CANCER RESEARCH（2018）

引用 1|浏览14

暂无评分

摘要

With great interest, we read the article by Kurland and colleagues ([1][1]) that investigates the value of 18F-fluoroestradiol (FES) and 18F-fluorodeoxyglucose (FDG) PET for the prediction of progression-free survival (PFS) in 84 patients with advanced, estrogen receptor (ER)–positive breast

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要